Humira, the injectable rheumatoid arthritis treatment is pictured in a pharmacy in Cambridge, Massachusetts on Wednesday, January 25, 2006. Abbott Laboratories said fourth-quarter sales were lifted by surging demand for its arthritis treatment while Bristol-Myers Squibb Co. said revenue fell as it faces a patent fight on its best-selling product. Photographer: JB Reed/Bloomberg News Credit: J.B. Reed/Bloomberg

Workers filled fewer prescriptions in 2023 than in 2022, and the drug that cost their employers the most was Humira — a drug that tries to keep people's immune systems from attacking their own cells — not the hot new GLP-1 agonist diabetes and obesity control drugs.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Allison Bell

Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Employer-Paid